137 related articles for article (PubMed ID: 38237101)
1. Somatic POLE Mutation and Ultra-Hypermutated Genotype in a De Novo High-Grade, Isocitrate Dehydrogenase Wild-Type Glioma: Treatment Implications.
Mundt D; Melguizo-Gavilanes I; Tumu AY; Dubner S; Walters MK; McFarlane L
JCO Precis Oncol; 2024 Jan; 8():e2300324. PubMed ID: 38237101
[TBL] [Abstract][Full Text] [Related]
2. Two Unique Glioma Subtypes Revealed.
Poh A
Cancer Discov; 2016 Apr; 6(4):334-5. PubMed ID: 26917670
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
Lu VM; McDonald KL
CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
[TBL] [Abstract][Full Text] [Related]
4. Targeting IDH in Low-Grade Glioma.
Claus EB; Verhaak RGW
N Engl J Med; 2023 Aug; 389(7):655-659. PubMed ID: 37585633
[No Abstract] [Full Text] [Related]
5. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
[TBL] [Abstract][Full Text] [Related]
6. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
7. A new era for glioma therapy - targeting mutant IDH.
Reardon DA; Cahill DP
Nat Rev Clin Oncol; 2023 Nov; 20(11):737-738. PubMed ID: 37460634
[No Abstract] [Full Text] [Related]
8. Recurrent high-grade astrocytoma with somatic mosaicism of isocitrate dehydrogenase gene mutation.
Masui K; Onizuka H; Nitta M; Muragaki Y; Kawamata T; Komori T
Pathol Int; 2023 Mar; 73(3):144-146. PubMed ID: 36645206
[No Abstract] [Full Text] [Related]
9. Targeted Options for Glioma Looking Good.
Cancer Discov; 2023 Aug; 13(8):1755. PubMed ID: 37276325
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Hodges TR; Choi BD; Bigner DD; Yan H; Sampson JH
J Neurosurg; 2013 Jun; 118(6):1176-80. PubMed ID: 23581583
[TBL] [Abstract][Full Text] [Related]
11. Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas.
Yu L; Qi ST; Li ZY
Chin Med J (Engl); 2010 Dec; 123(24):3697-705. PubMed ID: 22166653
[TBL] [Abstract][Full Text] [Related]
12. Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Schiff D; Purow BW
Nat Rev Neurol; 2009 Jun; 5(6):303-4. PubMed ID: 19498431
[TBL] [Abstract][Full Text] [Related]
13. 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma.
Federici L; Capelle L; Annereau M; Bielle F; Willekens C; Dehais C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY; Idbaih A; Lemare F; de Botton S; Sanson M; Touat M
Neuro Oncol; 2020 Aug; 22(8):1226-1228. PubMed ID: 32215616
[No Abstract] [Full Text] [Related]
14. Textiloma resembling anaplastic progression of an isocitrate dehydrogenase 1 (IDH1) mutant, low grade glioma.
Anderson MD; Raghunathan A; Gilbert MR
J Neurooncol; 2013 Feb; 111(3):377-9. PubMed ID: 23203443
[No Abstract] [Full Text] [Related]
15. Ivosidenib in Isocitrate Dehydrogenase 1
Mellinghoff IK; Ellingson BM; Touat M; Maher E; De La Fuente MI; Holdhoff M; Cote GM; Burris H; Janku F; Young RJ; Huang R; Jiang L; Choe S; Fan B; Yen K; Lu M; Bowden C; Steelman L; Pandya SS; Cloughesy TF; Wen PY
J Clin Oncol; 2020 Oct; 38(29):3398-3406. PubMed ID: 32530764
[TBL] [Abstract][Full Text] [Related]
16. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
Kim N; Kim SH; Kang SG; Moon JH; Cho J; Suh CO; In Yoon H; Chang JH
Radiat Oncol; 2020 Jul; 15(1):184. PubMed ID: 32736562
[TBL] [Abstract][Full Text] [Related]
17. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.
Shi DD; Savani MR; Levitt MM; Wang AC; Endress JE; Bird CE; Buehler J; Stopka SA; Regan MS; Lin YF; Puliyappadamba VT; Gao W; Khanal J; Evans L; Lee JH; Guo L; Xiao Y; Xu M; Huang B; Jennings RB; Bonal DM; Martin-Sandoval MS; Dang T; Gattie LC; Cameron AB; Lee S; Asara JM; Kornblum HI; Mak TW; Looper RE; Nguyen QD; Signoretti S; Gradl S; Sutter A; Jeffers M; Janzer A; Lehrman MA; Zacharias LG; Mathews TP; Losman JA; Richardson TE; Cahill DP; DeBerardinis RJ; Ligon KL; Xu L; Ly P; Agar NYR; Abdullah KG; Harris IS; Kaelin WG; McBrayer SK
Cancer Cell; 2022 Sep; 40(9):939-956.e16. PubMed ID: 35985343
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
[TBL] [Abstract][Full Text] [Related]
19. Does early identification of low-grade glioma growth impact outcome?
Chamberlain MC
Neuro Oncol; 2014 Sep; 16(9):1296. PubMed ID: 25125165
[No Abstract] [Full Text] [Related]
20. Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and Oncogene Activation in Gliomas.
Starke RM; Connolly ES; Komotar RJ
Neurosurgery; 2016 Jun; 78(6):N20-2. PubMed ID: 27191813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
